Physician profile
Robert D Steiner
NPI 1982612420
$77,372.26
in general payments reported to CMS, 2019-2025
9 companies · $23K in 2025
The $23K reported for 2025 was more than what 91% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $574 · 2021: $5,550 · 2022: $4,656 · 2023: $19K · 2024: $25K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $57K · Travel and Lodging: $7,437 · Food and Beverage: $1,937 · Education: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $56,804.68 |
| Travel and Lodging | $7,436.55 |
| Food and Beverage | $1,937.17 |
| Education | $414.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $40,643.10 | 2023-2025 | Cholbam, Chenodal, Cholbam |
| Travere Therapeutics, INC. | $15,160.45 | 2020-2023 | Chenodal |
| Ptc Therapeutics, INC. | $10,701.71 | 2020-2023 | Emflaza |
| Amgen INC. | $8,232.65 | 2025 | Procysbi, Ravicti |
| Leadiant Biosciences, INC. | $2,325.00 | 2022-2023 | |
| Biomarin Pharmaceutical INC. | $156.28 | 2022 | |
| Genzyme Corporation | $127.97 | 2024 | |
| Orchard Therapeutics North America | $25.10 | 2025 | Lenmeldy |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Steiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.